C4 Therapeutics, Chemours, CBRE, Corteva Report Key Stock Movements

Recent insider trading activities have raised interest among investors regarding the future prospects of several companies. C4 Therapeutics Inc's insider trading includes Salter Malcolm purchasing 13,000 shares, prompting analysts to upgrade the stock's rating to 'Overweight' with a price target increase. CBRE Group Inc saw Queenan Daniel G sell 10,000 shares, leading to a mixed analyst outlook with recent upgrades and downgrades reflected in the stock's price target adjustment. Chemours Company's insider Scarborough Alvenia sold and then purchased shares, with analysts maintaining a 'Buy' rating while the stock has shown a steady increase over the year. Meanwhile, Corteva Inc's FUERER CORNEL B executed significant trades, resulting in a variety of ratings from analysts, while the stock has also performed well in the past year. Each company's stock performance is closely monitored, reflecting the impact of insider actions and analyst sentiments on market expectations.